<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300231</url>
  </required_header>
  <id_info>
    <org_study_id>1905006917</org_study_id>
    <nct_id>NCT04300231</nct_id>
  </id_info>
  <brief_title>Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy</brief_title>
  <official_title>Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the difference between four different pain control&#xD;
      methods in patients who will be having a cystectomy surgery (surgical removal of the&#xD;
      bladder).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the difference between four different pain control&#xD;
      methods in patients who will be having a cystectomy surgery (surgical removal of the&#xD;
      bladder). By collecting this data, we aim to show improved postoperative pain scores,&#xD;
      decreased opioid needs, and decreased opioid side effects (feeling sick to your stomach,&#xD;
      feeling drowsy/sleepy, blockage/lack of movement in the intestines, inability to completely&#xD;
      empty the bladder, unusually slow or shallow breathing).&#xD;
&#xD;
      The specific aim of this study is to compare the difference between the pain control methods&#xD;
      in achieving the following:&#xD;
&#xD;
        1. Decreased opioid requirements&#xD;
&#xD;
        2. Improved postoperative VAS pain scores&#xD;
&#xD;
        3. Decreased opioid side effects (Nausea, sedation, ileus, respiratory depression)&#xD;
&#xD;
        4. Decreased hospital length of stay (LOS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Thoracic Epidural Analgesia&#xD;
Rectus Sheath Block&#xD;
Surgeon Infiltration with Liposomal Bupivacaine&#xD;
Standard Bupivacaine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Sedation score at 1 hour</measure>
    <time_frame>1 hour</time_frame>
    <description>Sedation scores will be collected by a study team member post operatively at hour 1 per protocol requirements. Determining if patient is awake &amp; alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Sedation score at 24 hour</measure>
    <time_frame>24 hour</time_frame>
    <description>Sedation scores will be collected by a study team member post operatively at hour 24 per protocol requirements. Determining if patient is awake &amp; alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Sedation score at 48 hour</measure>
    <time_frame>48 hour</time_frame>
    <description>Sedation scores will be collected by a study team member post operatively at hour 48 per protocol requirements. Determining if patient is awake &amp; alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Sedation score at 72 hour</measure>
    <time_frame>72 hour</time_frame>
    <description>Sedation scores will be collected by a study team member post operatively at hour 72 per protocol requirements. Determining if patient is awake &amp; alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Sedation score at 96 hour</measure>
    <time_frame>96 hour</time_frame>
    <description>Sedation scores will be collected by a study team member post operatively at hour 96 per protocol requirements. Determining if patient is awake &amp; alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First Flatus</measure>
    <time_frame>Assess daily until patient passes gas postoperatively</time_frame>
    <description>The passing of gas will be collected by a study team member as per protocol requirements. This is only for the first time the patients passes gas post operatively and is expected to occur during the hospital admission prior to patients discharge. The outcome measure will be assessed through study completion, an average of 1week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Creatinine</measure>
    <time_frame>Creatinine level will be collected daily postoperatively for 4 days</time_frame>
    <description>Lab level of Creatinine will be collected if only ordered by the surgeon doing the surgery. I will be recorded or documented for 4 days post operatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-emetic usage</measure>
    <time_frame>1 hour</time_frame>
    <description>nausea medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-emetic usage</measure>
    <time_frame>24 hour</time_frame>
    <description>nausea medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-emetic usage</measure>
    <time_frame>48 hour</time_frame>
    <description>nausea medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-emetic usage</measure>
    <time_frame>72 hour</time_frame>
    <description>nausea medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-emetic usage</measure>
    <time_frame>96 hour</time_frame>
    <description>nausea medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint includes total opioid consumption at 1 hour</measure>
    <time_frame>Opioid comsumption will be measured at 1 hour</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively at hour 1 per protocol time requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint includes total opioid consumption at 24 hours</measure>
    <time_frame>Opioid comsumption will be measured at 24 hours</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively at hour 24 per protocol time requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint includes total opioid consumption at 48 hours</measure>
    <time_frame>Opioid comsumption will be measured at 48 hours</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively at hour 48 per protocol time requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint includes total opioid consumption at 72 hours</measure>
    <time_frame>Opioid comsumption will be measured at 72 hours</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively at hour 72 per protocol time requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint includes total opioid consumption at 96 hours</measure>
    <time_frame>Opioid comsumption will be measured at 96 hours</time_frame>
    <description>Opioid consumption will be collected by a study team member post operatively at hour 96 per protocol time requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at 1 hour</measure>
    <time_frame>Pain scores will be measured 1 hour after surgery</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at 24</measure>
    <time_frame>Pain scores will be measured 24 hours after surgery</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at 48 hour</measure>
    <time_frame>Pain scores will be measured 48 hours after surgery</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at 72 hour</measure>
    <time_frame>Pain scores will be measured 72 hours after surgery</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS score at 96 hour</measure>
    <time_frame>Pain scores will be measured 96 hours after surgery</time_frame>
    <description>The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Nausea score 1 hour</measure>
    <time_frame>1 hour</time_frame>
    <description>Nausea scores will be collected by study team member post operatively at hour 1 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Nausea score 24 hour</measure>
    <time_frame>24 hour</time_frame>
    <description>Nausea scores will be collected by study team member post operatively at hour 24 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Nausea score 48 hour</measure>
    <time_frame>48 hour</time_frame>
    <description>Nausea scores will be collected by study team member post operatively at hour 48 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Nausea score 72 hour</measure>
    <time_frame>72 hour</time_frame>
    <description>Nausea scores will be collected by study team member post operatively at hour 72 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Nausea score 96 hour</measure>
    <time_frame>96 hour</time_frame>
    <description>Nausea scores will be collected by study team member post operatively at hour 96 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cystectomy</condition>
  <arm_group>
    <arm_group_label>Thoracic epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1. Thoracic epidural- epidural bupivacaine 0.05%/hydromorphone 0.05mg/ml mix will be given throughout the duration of their epidural analgesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rectus Sheath Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2. Rectus Sheath Block - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected into 4 locations below the rectus abdominis muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgeon Infiltration with Liposomal Bupivacaine (LB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3. Surgeon infiltration with Liposomal Bupivacaine (LB) - 20 mL of Exparel® diluted with 40 mL of 0.125% bupivacaine and 40 ml of injectable saline for a total of 100 mL. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery, prior to abdominal wall closure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgeon Infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4. Surgeon infiltration with Standard Bupivacaine (SB) - 60ml of 0.25% bupivacaine will be diluted with 40ml of saline for a total of 100ml. The 100 mL will be injected throughout the incision site by the surgeon at the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epidural bupivacaine 0.05%</intervention_name>
    <description>Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.</description>
    <arm_group_label>Thoracic epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>20 ml</description>
    <arm_group_label>Rectus Sheath Block</arm_group_label>
    <arm_group_label>Surgeon Infiltration with Liposomal Bupivacaine (LB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine 0.125%</intervention_name>
    <description>40 mL</description>
    <arm_group_label>Rectus Sheath Block</arm_group_label>
    <arm_group_label>Surgeon Infiltration with Liposomal Bupivacaine (LB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine 0.5%</intervention_name>
    <description>60 mL</description>
    <arm_group_label>Surgeon Infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>/hydromorphone 0.05mg/ml</intervention_name>
    <description>Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.</description>
    <arm_group_label>Thoracic epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injectable saline</intervention_name>
    <description>40 mL</description>
    <arm_group_label>Rectus Sheath Block</arm_group_label>
    <arm_group_label>Surgeon Infiltration</arm_group_label>
    <arm_group_label>Surgeon Infiltration with Liposomal Bupivacaine (LB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing cystectomy for bladder cancer&#xD;
&#xD;
          -  ASA class 1, 2, 3 or 4&#xD;
&#xD;
          -  Age 18 or older, male or female&#xD;
&#xD;
          -  Desires Regional anesthesia for postoperative pain control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication for thoracic epidural.&#xD;
&#xD;
          -  History of substance abuse in the past 6 months.&#xD;
&#xD;
          -  Patients on more than 30mg morphine equivalents of opioids daily.&#xD;
&#xD;
          -  Any physical, mental or medical conditions which in the opinion of the investigators,&#xD;
             may confound quantifying postoperative pain resulting from surgery.&#xD;
&#xD;
          -  Known allergy or other contraindications to the study medications (Acetaminophen,&#xD;
             Gabapentin, Bupivacaine, Hydromorphone).&#xD;
&#xD;
          -  Postoperative intubation.&#xD;
&#xD;
          -  Any patient with history of neuropathic bowel or bladder dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yar Yeap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyla Farlow, LPN</last_name>
    <phone>317-948-9804</phone>
    <email>lychrist@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angie Plummer, LPN</last_name>
    <phone>317-944-7239</phone>
    <email>plummera@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana Univeristy</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyla Farlow, LPN</last_name>
      <phone>317-984-9804</phone>
      <email>lychrist@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angie Plummer, LPN</last_name>
      <phone>317-944-7239</phone>
      <email>plummera@iupui.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Butterworth Iv, John F., David C. Mackey, and John D. Wasnick.</citation>
  </reference>
  <reference>
    <citation>de Boer, H. D., O. Detriche, and P. Forget.</citation>
  </reference>
  <reference>
    <citation>Guo, Q., R. Li, L. Wang, D. Zhang, and Y. Ma.</citation>
  </reference>
  <reference>
    <citation>Hou X, Luo Z, Wang H, Zhan Y, Yang L, Li L. [Effect of adductor canal block combined with local infiltration anesthesia on rehabilitation of primary total knee arthroplasty]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2018 Aug 15;32(8):1006-1011. doi: 10.7507/1002-1892.201801082. Chinese.</citation>
    <PMID>30238727</PMID>
  </reference>
  <reference>
    <citation>Kalogera E, Bakkum-Gamez JN, Weaver AL, Moriarty JP, Borah BJ, Langstraat CL, Jankowski CJ, Lovely JK, Cliby WA, Dowdy SC. Abdominal Incision Injection of Liposomal Bupivacaine and Opioid Use After Laparotomy for Gynecologic Malignancies. Obstet Gynecol. 2016 Nov;128(5):1009-1017. doi: 10.1097/AOG.0000000000001719.</citation>
    <PMID>27741199</PMID>
  </reference>
  <reference>
    <citation>Ladjevic, N., I. Likic-Ladjevic, Z. Dzamic, M. Acimovic, D. Dragicevic, and O. Durutovic.</citation>
  </reference>
  <reference>
    <citation>Mazul-Sunko B, Gilja I, Jelisavac M, Kožul I, Troha D, Osmančević N, El-Saleh A, Markić A, Kovačević M, Bokarica P. Thoracic epidural analgesia for radical cystectomy improves bowel function even in traditional perioperative care: a retrospective study in eighty-five patients. Acta Clin Croat. 2014 Sep;53(3):319-25.</citation>
    <PMID>25509242</PMID>
  </reference>
  <reference>
    <citation>Ozyuvaci E, Altan A, Karadeniz T, Topsakal M, Besisik A, Yucel M. General anesthesia versus epidural and general anesthesia in radical cystectomy. Urol Int. 2005;74(1):62-7.</citation>
    <PMID>15711112</PMID>
  </reference>
  <reference>
    <citation>ozek, J. J., M. De Ruyter, and T. W. Khan.</citation>
  </reference>
  <reference>
    <citation>Ablikim M, Achasov MN, An L, An Q, An ZH, Bai JZ, Baldini R, Ban Y, Becker J, Berger N, Bertani M, Bian JM, Bondarenko O, Boyko I, Briere RA, Bytev V, Cai X, Cao GF, Cao XX, Chang JF, Chelkov G, Chen G, Chen HS, Chen JC, Chen ML, Chen SJ, Chen Y, Chen YB, Cheng HP, Chu YP, Cronin-Hennessy D, Dai HL, Dai JP, Dedovich D, Deng ZY, Denysenko I, Destefanis M, Ding Y, Dong LY, Dong MY, Du SX, Duan MY, Fan RR, Fang J, Fang SS, Feng CQ, Fu CD, Fu JL, Gao Y, Geng C, Goetzen K, Gong WX, Greco M, Grishin S, Gu MH, Gu YT, Guan YH, Guo AQ, Guo LB, Guo YP, Hao XQ, Harris FA, He KL, He M, He ZY, Heng YK, Hou ZL, Hu HM, Hu JF, Hu T, Huang B, Huang GM, Huang JS, Huang XT, Huang YP, Hussain T, Ji CS, Ji Q, Ji XB, Ji XL, Jia LK, Jiang LL, Jiang XS, Jiao JB, Jiao Z, Jin DP, Jin S, Jing FF, Kavatsyuk M, Komamiya S, Kuehn W, Lange JS, Leung JK, Li C, Li C, Li DM, Li F, Li G, Li HB, Li JC, Li L, Li NB, Li QJ, Li WD, Li WG, Li XL, Li XN, Li XQ, Li XR, Li ZB, Liang H, Liang YF, Liang YT, Liao GR, Liao XT, Liu BJ, Liu BJ, Liu CL, Liu CX, Liu CY, Liu FH, Liu F, Liu F, Liu GC, Liu H, Liu HB, Liu HM, Liu HW, Liu JP, Liu K, Liu KY, Liu Q, Liu SB, Liu X, Liu XH, Liu YB, Liu YW, Liu Y, Liu ZA, Liu ZQ, Loehner H, Lu GR, Lu HJ, Lu JG, Lu QW, Lu XR, Lu YP, Luo CL, Luo MX, Luo T, Luo XL, Ma CL, Ma FC, Ma HL, Ma QM, Ma T, Ma X, Ma XY, Maggiora M, Malik QA, Mao H, Mao YJ, Mao ZP, Messchendorp JG, Min J, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Ning Z, Olsen SL, Ouyang Q, Pacetti S, Pelizaeus M, Peters K, Ping JL, Ping RG, Poling R, Pun CS, Qi M, Qian S, Qiao CF, Qin XS, Qiu JF, Rashid KH, Rong G, Ruan XD, Sarantsev A, Schulze J, Shao M, Shen CP, Shen XY, Sheng HY, Shepherd MR, Song XY, Sonoda S, Spataro S, Spruck B, Sun DH, Sun GX, Sun JF, Sun SS, Sun XD, Sun YJ, Sun YZ, Sun ZJ, Sun ZT, Tang CJ, Tang X, Tang XF, Tian HL, Toth D, Varner GS, Wan X, Wang BQ, Wang K, Wang LL, Wang LS, Wang M, Wang P, Wang PL, Wang Q, Wang SG, Wang XL, Wang YD, Wang YF, Wang YQ, Wang Z, Wang ZG, Wang ZY, Wei DH, Wen QG, Wen SP, Wiedner U, Wu LH, Wu N, Wu W, Wu Z, Xiao ZJ, Xie YG, Xu GF, Xu GM, Xu H, Xu Y, Xu ZR, Xu ZZ, Xue Z, Yan L, Yan WB, Yan YH, Yang HX, Yang M, Yang T, Yang Y, Yang YX, Ye M, Ye MH, Yu BX, Yu CX, Yu L, Yuan CZ, Yuan WL, Yuan Y, Zafar AA, Zallo A, Zeng Y, Zhang BX, Zhang BY, Zhang CC, Zhang DH, Zhang HH, Zhang HY, Zhang J, Zhang JW, Zhang JY, Zhang JZ, Zhang L, Zhang SH, Zhang TR, Zhang XJ, Zhang XY, Zhang Y, Zhang YH, Zhang ZP, Zhang ZY, Zhao G, Zhao HS, Zhao J, Zhao J, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao TC, Zhao XH, Zhao YB, Zhao ZG, Zhao ZL, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zheng ZP, Zhong B, Zhong J, Zhong L, Zhou L, Zhou XK, Zhou XR, Zhu C, Zhu K, Zhu KJ, Zhu SH, Zhu XL, Zhu XW, Zhu YS, Zhu ZA, Zhuang J, Zou BS, Zou JH, Zuo JX, Zweber P; BESIII Collaboration. Observation of χ(c1) decays into vector meson pairs φφ, ωω, and ωφ. Phys Rev Lett. 2011 Aug 26;107(9):092001. Epub 2011 Aug 22.</citation>
    <PMID>21929228</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>May 22, 2021</last_update_submitted>
  <last_update_submitted_qc>May 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Yar Yeap</investigator_full_name>
    <investigator_title>Director, Acute Pain Service, Assistant Professor of Clinical Anesthesiology, Dept of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

